Article Text

Download PDFPDF
Tuberculous tonsillitis in a patient receiving etanercept treatment
  1. C T Derk,
  2. R J DeHoratius
  1. Department of Rheumatology, Thomas Jefferson University, Room 613, Curtis Bldg, 1015 Walnut Street, Philadelphia, PA 19107, USA
  1. Correspondence to
    Dr C T Derk;

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Since the approval by the Food and Drug Administration (FDA) of tumour necrosis factor α antagonists, infections have accounted for 21% of the adverse events reported to the FDA for etanercept and 20% of those reported for infliximab.1,2

As of May 2001, from approximately 147 000 subjects receiving infliximab treatment, 70 patients have been reported to have developed active tuberculosis. Of these, 52% presented with extrapulmonary tuberculosis while 24% presented with disseminated disease.3 As of April 2001, from approximately 102 000 subjects receiving etanercept treatment, nine patients have been reported to have developed active tuberculosis.4 With the …

View Full Text